The ESH 3rd Translational Research Conference on Erythropoiesis Control and Ineffective Erythropoiesis "From Bench to Bedside", which will held in Paris on 3-5 March 2023 aims to provide an education programme on basic science related to normal and pathological erythropoiesis and megakaryopoiesis, giving opportunities to share experiences in clinical practice. Chairs: Maria-Domenica Cappellini, Michaela Fontenay, Stuart Orkin

Date: Friday 3 - Sunday 5 March 2023
Venue: Novotel Paris Tour Eiffel, France

ESH Translational Research Conferences address leading-edge biological, clinical and therapeutic questions from state-of-the-art to future perspectives.

Erythropoiesis is a continuous process leading to the daily production of 1011 red cells. The bone marrow microenvironment supports and educates the hematopoietic progenitors. Recent advances deeply increase our understanding of erythropoiesis control and its deregulation in pathological conditions thanks to the studies of chromatin organisation and post-transcriptional regulatory mechanisms occurring during erythroid cell differentiation. Ineffective erythropoiesis relies on various mechanisms that may combine in some diseases or demonstrate specificities supporting particular phenotypes and opening the avenue for targeted therapies. Identifying the causes of treatment resistance and following the dynamics of erythroid response will provide valuable information to improve patients care through the design of innovative clinical trials.

Continuing Medical Education (CME) credit points will be awarded to physicians for the time they will spend at the meeting improving their knowledge and skills. ESH is a provider of the European Haematology CME system.

Posters and Brief Oral Communications:

Registered participants are invited to submit their biology and clinical abstracts. Selected abstracts will be presented as brief oral communications or posters.

Call for abstracts: deadline 2 January 2023

This meeting will be valuable to you if you are looking for:

  • A cutting-edge scientific program – from basic science to clinical and therapeutic applications and perspectives
  • Multiple opportunities for scientific interaction with an international faculty of distinguished experts
  • An emphasis on critical discussion The meeting will provide clinicians and scientists with state-of-the-art recommendations regarding patient care and insight in controversies in the field.

The meeting will be of interest to:

  • Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
  • Junior scientists and clinicians (MD, PhD)
  • PhD candidates and clinical residents still in-training

Learning Objectives:

  • Increasing our understanding of regulatory mechanisms of erythropoiesis
  • Post-transcriptional regulation of erythropoiesis Listing the causes of ineffective erythropoiesis and the potential targets for innovative treatments

Scientific Topics:

  • Metabolism in erythroid cells
  • Proteome remodeling and cellular clearance in erythropoiesis
  • Fetal globin silencing
  • Bone marrow cell expansion and engraftment
  • Stressed erythropoiesis in MDS
  • Stressed erythropoiesis in haemoglobinopathies and other haemolytic anaemia
  • Clinical and diagnosis
  • Gene therapy and genome editing
  • Pharmacological approaches

The programme will include:

  • Keynote Lectures
  • Plenary Sessions
  • Simultaneous Meet the Experts Sessions
  • Round Table Discussions
  • Poster Presentations
  • Short Oral Communications
  • Ample time for in-depth discussion

Conference website and registration

External Events

Nov 24
22
26
November 22nd 2024
Immunomodulation Update Day
This year’s Immunomodulation Update Day will include sessions focussing on advances in the biology and science, curre...
Details
November 26th 2024
Current Thinking in Haematological Maligancies
Current Thinking in Haematological Malignancies.
Details
November 26th 2024
UCLH 'Caring for the Critically Ill Haematology...
Ten topics will cover a range of acute presentations from amyloidosis to ICANS to HLH.
Details